We are recruiting patients for the PTP ATRI-015 study

The PSP Clinical Trial Platform (PTP) study is a multicenter, multi-regimen, Phase 2, randomized, double-blind, placebo-controlled, perpetual platform clinical trial, designed to evaluate the safety and efficacy of multiple investigational products simultaneously or sequentially in mild-to moderate Progressive Supranuclear Palsy (PSP).

The primary objective of this study is to evaluate the efficacy of multiple investigational products on PSP disease progression and determine whether the investigational products are safe and well-tolerated in participants with mild-to-moderate PSP. The primary endpoint is the change from baseline on the mPSPRS-15 over 52 weeks.

Investigational products will be tested in regimens. Each regimen will consist of an investigational product and a placebo. Approximately 440 participants will be enrolled across approximately 50 clinical sites in North America.

We are looking for people aged 41-86 who have:

- Clinical diagnosis of possible or probable PSP Richardson's Syndrome phenotype defined by the 2017 MDS criteria with presence of PSP symptoms less than 5 years onset.
- MMSE score of 25 or lower.
- A reliable study partner who spends sufficient time with the participant and is willing and able to attend study visits and answer questions.

And who have not had:

- Blood transfusion within 4 weeks of screening.
- Prior or current treatment with either anti-tau or anti-amyloid agents
- History of immunodeficiency disorders and autoimmune diseases that may require immunomodulatory medications.

*Please note that there are additional criteria for participation.

Screening window lasting up to 44 days.

Study visits every 4 weeks.

Optional open-label extension period of 52 weeks offered to all participants following trial completion.

If you have any questions or would like to discuss the referral of a patient, please contact us.

PTP ATRI-015 Study Team:

Study Coordinator: Bailey Wolf
Email: bwolf3@uw.edu
Phone: (253) 266-5505

Principal Investigator: Michael Rosenbloom